Skip to main content
. Author manuscript; available in PMC: 2024 Aug 20.
Published in final edited form as: Lancet Infect Dis. 2022 Jun 21;22(9):1365–1373. doi: 10.1016/S1473-3099(22)00234-1

Table 1:

Characteristics of persons with cryptococcal meningitis on flucytosine-based combination treatment versus other induction regimens at 19 facilities with flucytosine access, South Africa, July 2018-March 2020

Characteristics n/N (%) 5FC-containing regimens, n=596
n (%)
Other regimens, n=943
n (%)
p-value
Age in years; median (IQR) 1,537 37 (32-43) 36 (31-43) 0.08a
Age category, years 1,537
≥18-29 280 (18) 97 (16) 183 (19) 0.11
30-39 679 (44) 269 (45) 410 (44)
40-49 394 (26) 167 (28) 227 (24)
>49 184 (12) 63 (11) 121 (13)
Sex 1539
Male 906 (59) 341 (57) 565 (60) 0.29
Female 633 (41) 255 (43) 378 (60)
Province of sentinel site hospital 1,539
Gauteng 525 (34) 255 (43) 270 (29) <0.001
KwaZulu-Natal 316 (21) 25 (4) 291 (31)
Eastern Cape 308 (20) 168 (28) 140 (15)
Limpopo 43 (3) 3 (1) 40 (4)
North West 131 (9) 56 (9) 75 (8)
Western Cape 66 (4) 23 (4) 43 (5)
Mpumalanga 86 (6) 48 (8) 38 (4)
Free State 52 (3) 16 (2) 36 (4)
Northern Cape 12 (1) 2 (1) 10 (1)
CD4 count (cells/mm3) 1,435
<100 1,154 (80) 438 (81) 633 (80) 0.76
≥100 281 (20) 106 (19) 160 (20)
Viral load (log10 RNA copies/mL) 1,151
<400-10000 378 (33) 155 (34) 176 (31) 0.29
>10000 773 (67) 296 (66) 388 (69)
Antiretroviral therapy 1,517
Naive 576 (38) 266 (66) 441 (73) 0.01
Experienced 941 (62) 139 (34) 163 (27)
Glasgow Coma Scale score <15 1377
No 994 (72) 377 (73) 617 (72) 0.64
Yes 383 (28) 140 (27) 243 (28)
CSF opening pressure of >20 cm H20 384
No 101 (26) 60 (26) 41 (26) 0.96
Yes 283 (74) 169 (74) 114 (74)
Concurrent TB treatment 1,513
No 1,098 (73) 412 (70) 686 (74) 0.12
Yes 415 (27) 174 (30) 241 (26)
Headache at diagnosis 1,482
No 179 (12) 52 (9) 127 (14) 0.004
Yes 1,303 (88) 525 (91) 778 (86)

Data are n (%) or n (%)/N. 5-FC=flucytosine. CSF=cerebrospinal fluid. IQR=interquartile range. TB=tuberculosis. aKruskal-Wallis test